martes, 13 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callYahoo Finance· February 13, 2026

Credicorp Q4 Earnings Call Highlights

View original at finance.yahoo.com
Credicorp Q4 Earnings Call Highlights Credicorp logo Key Points Credicorp closed 2025 with “record high net income” and strong profitability — ROE 19% for the year and 16.9% in Q4 — while credit metrics improved to a NPL ratio of 4.5%, cost of risk 1.8% and NPL coverage 112.4%…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Peru has an estimated $64 billion mining investment pipeline for 2025, up 17% from 2024

    80% confidence
  • Helm Bank acquisition aligned with niche strategy to enhance U.S. offering without pursuing universal banking model

    80% confidence
  • NPL volumes contracted across segments

    80% confidence
  • Mibanco's NPA ratio fell to 5.3%, an 11-year low

    80% confidence
  • Domestic demand in Peru grew close to 6% in 2025

    80% confidence
  • Yape lending mix shifting from very short-term monocuota loans to longer-duration multicuota loans, increasing duration from under one month to more than six months

    80% confidence
  • Yape closed 2025 with nearly 16 million monthly active users and average engagement of 66 transactions per month

    80% confidence
  • Expected cost of risk for Yape should remain controlled, with risk-adjusted NIM expected to remain at comparable levels

    80% confidence
  • Meaningful upside potential if copper and gold prices remain elevated and post-election environment improves policy predictability

    80% confidence
  • Credicorp ended 2025 with record high net income

    80% confidence
  • Peru had record exports above $90 billion in 2025

    80% confidence
  • Risk-adjusted revenues from innovation portfolio represented 8.1% by Q4, progressing toward 10% goal

    80% confidence
  • BCP served more than 3.2 million loan clients

    80% confidence
  • Yape's NPS peaked at 81 by year-end and monthly revenue per MAU reached PEN 9.6 as of December 2025

    80% confidence
  • Credicorp delivered 16.9% ROE in Q4 and 19% for full year, reflecting diversification and continued improvements in risk metrics

    80% confidence
  • BCP and Mibanco expected to grow loans at double-digit pace (around 11% at constant exchange rates) in 2026

    80% confidence
  • Peru GDP growth expected at about 3.5% in 2026, with domestic demand expanding above 4%

    80% confidence
  • Digital initiatives expected to be ROE-positive beginning in 2026

    80% confidence
  • Peru's economy exceeded expectations in 2025, with GDP growing around 3.5%

    80% confidence
  • Credicorp intends to revisit midterm ROE outlook after elections, potentially updating targets north of 20%

    80% confidence
  • Rafael López Aliaga leading Peru presidential poll at 12% and Keiko Fujimori at 8%, with large share of undecided or blank votes around 42%

    80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,372 documentos fuente archivados
Consulta estos datos → isubstrate.com